Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02034552 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
A Phase 2 study of Prostatic Neoplasms, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 19
- Study locations
NCT02034552 is a Phase 2 study of Prostatic Neoplasms that has completed, run by Bayer. The registered enrollment target is 68 participants, below the 513-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (87% lower). The trial reports 19 study locations across 16 states.
The verdict
NCT02034552, a Phase 2 study of Prostatic Neoplasms, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 19
- Study locations
Study Summary
The primary objective in this study is to evaluate bone scan response at Week 24 based on the quantified technetium-99 bone scan lesion area (BSLA). The safety of radium-223 dichloride in combination with abiraterone acetate or enzalutamide will be investigated. The study will evaluate radiological progression free survival, overall survival, and skeletal events. This study will also explore the clinical utility of different imaging modalities (whole body quantified technetium-99 bone scan, DW-MRI \[diffusion-weighted magnetic resonance imaging\] and NaF \[sodium fluoride\] PET-CT \[positron emission tomography-computed tomography\] scan) and will have a separate central radiological review for applicable secondary and exploratory imaging endpoints. All subjects will be randomized as assigned randomly by the IXRS (interactive voice / web response system) system in a 1:1:1 ratio into one of the treatment arms: radium-223 dichloride alone, 50 kBq/kg (55 kBq/kg after implementation of NIST \[National Institute of Standards and Technology\] update) every 4 weeks for up to 6 doses; radium-223 dichloride, 50 kBq/kg (55 kBq/kg after implementation of NIST update) every 4 weeks up to 6 doses together with abiraterone acetate 1,000 mg daily and prednisone 5 mg bid (twice daily); radium-223 dichloride 50 kBq/kg (55 kBq/kg after implementation of NIST update) every 4 weeks up to 6 doses together with enzalutamide 160 mg daily. The study will consist of screening, treatment and follow-up periods. Study will continue until disease progression as determined by investigator, or when patient meets criteria for withdrawal from study. Subjects in treatment arms with abiraterone/prednisone or enzalutamide will have the option to continue taking oral study therapy until the end of the study (2 years from the last dose of radium-223 dichloride) if the investigator deems the subject may benefit and there is no clinical or radiological progression. Subjects who discontinue all study treat
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG Enzalutamide
- DRUG Abiraterone acetate
- DRUG Radium-223 dichloride (Xofigo, BAY88-8223)
Study Locations (19)
Arizona
- - Scottsdale
- - Tucson
Louisiana
- - New Orleans
- - Shreveport
New York
- - Syracuse
- - The Bronx
California
- - Los Angeles
Connecticut
- - New Haven
Delaware
- - Newark
District of Columbia
- - Washington D.C.
Florida
- - Plantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2014-03-07 |
| Est. Completion | 2018-06-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02034552
The ClinicalTrials.gov registry entry for NCT02034552 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 513-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (87% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which Prednisone is the first listed.
NCT02034552 reports 19 study locations spanning 16 distinct geographic areas - top geographies include Arizona, Louisiana, New York.
Frequently Asked Questions
What is clinical trial NCT02034552 about?
NCT02034552 is a clinical study titled "A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)". The primary objective in this study is to evaluate bone scan response at Week 24 based on the quantified technetium-99 bone scan lesion area (BSLA). The safety of radium-223 dichloride in combination with abiraterone acetate or enzalutamide will be investigated. The study will evaluate radiological ...
What is the current status of trial NCT02034552?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2014-03-07. Estimated completion is 2018-06-26.
What conditions does trial NCT02034552 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT02034552?
The interventions under investigation include: Prednisone (DRUG), Enzalutamide (DRUG), Abiraterone acetate (DRUG), Radium-223 dichloride (Xofigo, BAY88-8223) (DRUG).
Who is sponsoring clinical trial NCT02034552?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02034552 being conducted?
This trial has 19 study locations across Arizona, California, Connecticut, Delaware, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
RECRUITING · Phase 2
-
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
RECRUITING · Phase 2
-
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
ACTIVE NOT RECRUITING · Phase 2
-
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.